Hip fracture, skeletal fragility, osteoporosis and hormonal deprivation in elderly women.
Fractures of the hip have been shown to have a significant personal and societal impact in Western countries; this impact is largely borne by elderly women, and represents a substantial health care commitment in modern society. For many people a fracture of the proximal end of the femur represents a preterminal event of considerable cost, both in economic loss and psychosocial well-being. These fractures are generally recognized as a clinical complication of osteoporosis, and are one index of general skeletal fragility which is also manifested in fractures of the vertebrate and of the distal radius (Colles fracture). There is increasing evidence that hormonal deprivation in elderly women is directly related to loss of skeletal integrity and consequent fragility. There is also increasing evidence that hormonal substitution is effective in preventing this structural loss and fragility. Unfortunately, a therapeutic dilemma has arisen in that the preparation that seems to give optimal protection, conjugated estrogens, has also been reported to cause an increased incidence of endometrial carcinoma. The search for a preparation or dosage regimen of estrogens which simultaneously prevents skeletal atrophy and fragility and avoids the increased risk of malignancy must be a long-term goal.
D000368:Aged; D001851:Bone Diseases, Metabolic / Q000188:drug therapy; D004967:Estrogens / Q000172:deficiency; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006620:Hip Fractures / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology; D014594:Uterine Neoplasms / Q000139:chemically induced
D004967:Estrogens; D004966:Estrogens, Conjugated (USP)